Article Type
Changed
Tue, 09/25/2018 - 13:57
Display Headline
Panel discussion
Article PDF
Author and Disclosure Information

Domenic A. Sica, MD
Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University Health System, Richmond, VA

Gary Francis, MD
Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH

W.H. Wilson Tang, MD
Section of Heart Failure and Cardiac Transplantation Medicine, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH

Steven R. Goldsmith, MD
Division of Cardiology, Hennepin County Medical Center, Minneapolis, MN

Mihai Gheorghiade, MD
Divison of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, IL

Dr. Sica reported that he has no financial relationships that pose a potential conflict of interest with this article.

Dr. Francis reported that he is a consultant to and has done teaching and speaking for the Amgen, Merck, Novartis, and Otsuka corporations.

Dr. Tang reported that he has served as a consultant to the FlowMedica, Medtronic, Neurocrine Biosciences, and Otsuka corporations.

Dr. Goldsmith reported that he is a consultant to the Astellas corporation and is on the speakers’ bureaus of the Astellas and GlaxoSmithKline corporations.

Dr. Gheorghiade reported that he is a consultant to the GlaxoSmithKline, Medtronic, Otsuka, PDL BioPharma, Pfizer, and Sigma Tau corporations.

Publications
Page Number
S30-S33
Author and Disclosure Information

Domenic A. Sica, MD
Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University Health System, Richmond, VA

Gary Francis, MD
Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH

W.H. Wilson Tang, MD
Section of Heart Failure and Cardiac Transplantation Medicine, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH

Steven R. Goldsmith, MD
Division of Cardiology, Hennepin County Medical Center, Minneapolis, MN

Mihai Gheorghiade, MD
Divison of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, IL

Dr. Sica reported that he has no financial relationships that pose a potential conflict of interest with this article.

Dr. Francis reported that he is a consultant to and has done teaching and speaking for the Amgen, Merck, Novartis, and Otsuka corporations.

Dr. Tang reported that he has served as a consultant to the FlowMedica, Medtronic, Neurocrine Biosciences, and Otsuka corporations.

Dr. Goldsmith reported that he is a consultant to the Astellas corporation and is on the speakers’ bureaus of the Astellas and GlaxoSmithKline corporations.

Dr. Gheorghiade reported that he is a consultant to the GlaxoSmithKline, Medtronic, Otsuka, PDL BioPharma, Pfizer, and Sigma Tau corporations.

Author and Disclosure Information

Domenic A. Sica, MD
Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University Health System, Richmond, VA

Gary Francis, MD
Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH

W.H. Wilson Tang, MD
Section of Heart Failure and Cardiac Transplantation Medicine, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH

Steven R. Goldsmith, MD
Division of Cardiology, Hennepin County Medical Center, Minneapolis, MN

Mihai Gheorghiade, MD
Divison of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, IL

Dr. Sica reported that he has no financial relationships that pose a potential conflict of interest with this article.

Dr. Francis reported that he is a consultant to and has done teaching and speaking for the Amgen, Merck, Novartis, and Otsuka corporations.

Dr. Tang reported that he has served as a consultant to the FlowMedica, Medtronic, Neurocrine Biosciences, and Otsuka corporations.

Dr. Goldsmith reported that he is a consultant to the Astellas corporation and is on the speakers’ bureaus of the Astellas and GlaxoSmithKline corporations.

Dr. Gheorghiade reported that he is a consultant to the GlaxoSmithKline, Medtronic, Otsuka, PDL BioPharma, Pfizer, and Sigma Tau corporations.

Article PDF
Article PDF
Related Articles
Page Number
S30-S33
Page Number
S30-S33
Publications
Publications
Article Type
Display Headline
Panel discussion
Display Headline
Panel discussion
Citation Override
Cleveland Clinic Journal of Medicine 2006 June;73(suppl 2):S30-S33
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Fri, 08/31/2018 - 07:00
Un-Gate On Date
Fri, 08/31/2018 - 07:00
Use ProPublica
CFC Schedule Remove Status
Fri, 08/31/2018 - 07:00
Article PDF Media